eGFR · people with CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Albuminuria or proteinuria · people with CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Indoxyl sulfate · people with CKD
1 finding from 1 review
Change in any GI upset or intolerance · people with CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Microbiota composition · people with CKD
1 finding from 1 review
Faecalibacterium · people with CKD
1 finding from 1 review
Parabacteroides · people with CKD
1 finding from 1 review
Bifidobacteria · people with CKD
1 finding from 1 review
Ruminococcus · people with CKD
1 finding from 1 review
Graft function · people with CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Graft infection · people with CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Persistent kidney disease at any time after treatment · patients with IgAV
Prednisone showed no clear difference in persistent kidney disease at any time after treatment compared with placebo or supportive treatment (moderate certainty).
1 finding from 1 review
Any continuing kidney disease at 3 months (study with high risk of bias excluded) · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 3 months compared with placebo or supportive treatment (moderate certainty).
2 findings from 1 review
Children with any continuing kidney disease at 6 months · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 6 months compared with placebo or supportive treatment (moderate certainty).
1 finding from 1 review
Any continuing kidney disease at 12 months (study with high risk of bias excluded) · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 12 months compared with placebo or supportive treatment (low certainty).
2 findings from 1 review
Number developing severe kidney disease · patients with IgAV
Prednisone showed no clear difference in number developing severe kidney disease compared with placebo or supportive treatment (low certainty).
1 finding from 1 review
Number with complete remission: complete remission in initial steroid resistance · idiopathic steroid‐resistant nephrotic syndrome in children
1 finding from 1 review
Number with complete remission: complete remission in delayed steroid resistance · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes number with complete remission: complete remission in delayed… compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Complete remission · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes number with complete remission: complete remission in all patients compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Adverse events: bronchospasm/treatment discontinued · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: bronchospasm/treatment discontinued compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review